VTVT vTv Therapeutics Inc.

5.89
+0.09  (2%)
Previous Close 5.80
Open 5.85
Price To book -1.82
Market Cap 193265625
Shares 32,812,500
Volume 7,694
Short Ratio 5.89
Av. Daily Volume 25,323

SEC filingsSee all SEC filings

  1. 8-K - Current report 171090168
  2. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 171034888
  3. 8-K - Current report 171000827
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 171000798
  5. 8-K - Current report 17943115

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released August 2016. Primary endpoint met.
TTP399 - AGATA
Type 2 Diabetes
Phase 2 primary endpoint met - December 14, 2016.
TTP273 - LOGRA
Type 2 Diabetes
Phase 3 initiated 2Q 2015. Part A enrollment completed September 2016. Part B enrollment completion announced June 1, 2017. Data from Part A due early 2018. Part B due late 2018
Azeliragon - STEADFAST
Mild Alzheimer’s disease

Latest News

  1. vTv Therapeutics Presents Further Dose Response Analysis from Phase 2 Study of its GLP-1 Receptor Agonist at 53rd Annual Meeting of the European Association for the Study of Diabetes
  2. vTv Therapeutics snags funding for study of its diabetes-targeting drug
  3. JDRF and vTv Therapeutics Announce Collaboration on Phase 2 Study of Novel Treatment for Type 1 Diabetes
  4. ETFs with exposure to vTv Therapeutics, Inc. : September 1, 2017
  5. vTv Therapeutics, Inc. :VTVT-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
  6. vTv Therapeutics Announces Issuance of U.S. Patent Covering Methods of Treatment Using Azeliragon
  7. VTv Therapeutics reports 2Q loss
  8. vTv Therapeutics Reports Second Quarter 2017 Financial and Operational Results
  9. 'We're not going to be taken off' — vTv Therapeutics CEO responds to NASDAQ's delisting warning
  10. vTv Therapeutics to Present Two Posters at the 2017 Alzheimer's Association International Conference
  11. vTv Therapeutics Presents Data Highlighting Further Potential of TTP273 at American Diabetes Association 77th Scientific Sessions
  12. vTv Therapeutics to Present Two Posters at the American Diabetes Association’s 77th Scientific Sessions
  13. vTv Therapeutics Completes Enrollment of Part B of Pivotal Phase III STEADFAST Trial Evaluating Azeliragon for the Treatment of Patients with Mild Alzheimer’s Disease
  14. Corporate insiders have sold $4B in stock in 30 days; here's who's buying and selling in the Triad
  15. ETFs with exposure to vTv Therapeutics, Inc. : May 22, 2017
  16. vTv Therapeutics, Inc. :VTVT-US: Earnings Analysis: Q1, 2017 By the Numbers : May 5, 2017
  17. vTv Therapeutics Reports First Quarter 2017 Financial and Operational Results
  18. ETFs with exposure to vTv Therapeutics, Inc. : April 5, 2017
  19. vTv Therapeutics, Inc. :VTVT-US: Earnings Analysis: Q4, 2016 By the Numbers : March 15, 2017

SEC Filings

  1. 8-K - Current report 171090168
  2. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 171034888
  3. 8-K - Current report 171000827
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 171000798
  5. 8-K - Current report 17943115
  6. 10-Q - Quarterly report [Sections 13 or 15(d)] 17810272
  7. 8-K - Current report 17810016
  8. 8-K - Current report 17720672
  9. 8-K - Current report 17715673
  10. CT ORDER - Confidential treatment order 17714417